• CN 101,820,901 B
  • Filed: 08/11/2008
  • Issued: 11/30/2016
  • Est. Priority Date: 08/13/2007
  • Status: Active Grant
First Claim
Patent Images

1. derived from subtertian malaria worm (Plasmodium falciparum) circumsporozoite protein antigen with include 3D-MPL andThe purposes in preparing medicine combined by the pharmaceutically acceptable adjuvant of QS21, and wherein said circumsporozoite protein is expressed in malariaDisease infect pre-erythrocytic stage, described medicine for for infant prophylactic immunization resist malaria, wherein target group is less than 1 years oldInfant, wherein 3D-MPL and QS21 both exists with every dosage 25 μ

  • g, and the final volume of described dosage is 0.5ml, withAnd the described antigen derived from the circumsporozoite protein of subtertian malaria worm (Plasmodium falciparum) is polypeptide RTS'"'"'s and SHybrid particles form, wherein said RTS is by the following fusion protein constituted;

    methionine residue;

    3 aminoacid, Met AlaPro;

    One section of 189 aminoacid, represents the aminoacid 207 to 395 of subtertian malaria worm 3D7 strain circumsporozoite protein;


    4 aminoAcid, Pro Val Thr Asn, represent 4 carboxyl-terminal residues of adw serotype hepatitis b virus preS 2 albumen;

    With one section 226Individual aminoacid, limits the S protein of adw serotype hepatitis B virus.

View all claims

    Thank you for your feedback